Vetoquinol is one of the main international players in animal health, for livestock (cows, pigs) and pets (cats, dogs).
An independent group and a pure player, Vetoquinol innovates, develops, produces and markets veterinary drugs and non-medicinal products in Europe, North and South America and the Asia-Pacific region.
In 2020, our group registered sales revenue of €427.5m, with equal amounts coming from livestock and pets, through 24 countries directly and thanks to an established network of 100 partner distributors.
Since its creation in 1933, Vetoquinol has combined innovation and geographical diversification. The strengthening of the products portfolio and the acquisitions carried out in regions with high potential guarantee hybrid growth for the group. Today, Vetoquinol employs about 2,400 people.
2020 key figures
2020 turnover: € 427.5 million,
Essential products turnover: € 220.6 million
Breakdown of group turnover by activity:
- Pets (€ 256.7m) 60%
- Livestock (170.7 M €) 40%